EBF1 nuclear repositioning instructs chromatin refolding to promote therapy resistance in T leukemic cells
Zhou Y, Petrovic J, Zhao J, Zhang W, Bigdeli A, Zhang Z, Berger SL, Pear WS, Faryabi RB. Mol Cell. Available online 18 February 2022. doi: 10.1016/j.molcel.2022.01.015
Summary
While gene mutations can lead to drug resistance, researchers, including Warren S. Pear, MD, PhD, and senior author R. Babak Faryabi, PhD, in the Perelman School of Medicine at the University of Pennsylvania have identified an important, non-genetic adaptation that could also drive resistance to targeted therapy in T cell leukemia, a type of blood cell cancer. Their findings "EBF1 nuclear repositioning instructs chromatin refolding to promote therapy resistance in T leukemic cells" were published this month in Molecular Cell.
Read the Penn Medicine news release.
